Previous studies have shown that group II metabotropic glutamate receptors (mGluRs) are present on the peripheral terminals of primary sensory neurons, suggesting that they might be involved in nociception. In this study, we investigated the modulation of nociception by peripheral group II mGluRs and the molecular basis of this modulation. Subcutaneous injection of a group II mGluR agonist, 2R,4R 4-aminopyrrolidine-2,4-dicarboxylate (APDC), did not alter thermal sensitivity but blocked prostaglandin E 2 (PGE 2 )-induced thermal hyperalgesia. This effect was blocked by (2s)-2-amino-2-[(1s,2s)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid, a selective group II mGluR antagonist. In cultured primary sensory neurons, APDC blocked PGE 2 -induced potentiation of capsaicin responses, which was abolished when neurons were pretreated with pertussis toxin. Similar potentiating effects induced by forskolin but not 8-bromo-cAMP were also blocked by the activation of group II mGluRs. These results indicate that peripheral group II mGluRs act via inhibition of adenylyl cyclase to reverse the sensitization of capsaicin receptors and the thermal hyperalgesia induced by PGE 2 , and suggest that peripheral group II mGluRs might be targeted for therapeutic intervention in inflammatory pain states.
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Inflammatory pain, which is a major report by patients with inflammation (Levine and Reichling, 1999) , usually manifests as an increased response to painful stimuli (hyperalgesia) and pain sensation to previously innocuous stimuli (allodynia). During inflammation, a number of molecules, including prostaglandins, bradykinin, substance P, and others, are released into the injury site. Many of these inflammatory mediators sensitize primary afferent nociceptors via the cAMP/PKA pathway. Activation of adenylyl cyclase (AC) or PKA produces hyperalgesia, whereas PKA inhibitors reduce hyperalgesia (Taiwo and Levine, 1991) . One mechanism by which the cAMP/PKA pathway could induce sensitization is by modulating the principle channels that transduce sensory stimuli.
The vanilloid receptor 1 (VR1), also known as the capsaicin receptor, is a nonselective cation channel expressed predominantly in sensory neurons that functions to integrate a number of pain-inducing stimuli (Caterina et al., 1997; Tominaga et al., 1998) . VR1 is essential for inflammatory thermal hyperalgesia, because inflammation-induced thermal sensitization fails to develop in mice lacking VR1 (Caterina et al., 2000; Davis et al., 2000) . Prostaglandin E 2 (PGE 2 ), by activating G s to activate the cAMP/PKA pathway, enhances capsaicin receptor function (Pitchford and Levine, 1991; Lopshire and Nicol, 1997) ; this effect may mediate thermal hyperalgesia.
In addition to the well known inflammatory mediators mentioned above, glutamate is also released in peripheral tissues during inflammation (Omote et al., 1998; deGroot et al., 2000) . Glutamate activates ionotropic glutamate receptors (iGluRs), including NMDA, AMPA, and kainate receptors, as well as G-protein-coupled metabotropic glutamate receptors (mGluRs). Peripheral injection of glutamate induces mechanical and thermal hypersensitivity by activating both iGluRs and mGluRs (Carlton et al., 1995; Jackson et al., 1995; Zhou et al., 1996; Bhave et al., 2001; Walker et al., 2001) . Based on sequence homology and pharmacological properties, mGluRs are divided into three groups: group I (mGluR1 and mGluR5), group II (mGluR2 and mGluR3), and group III (mGluR4, mGluR6, mGluR7, and mGluR8). Group I mGluRs are localized on nociceptive primary afferent fibers in the skin; activation of peripheral group I mGluRs enhances nociception (Bhave et al., 2001; Walker et al., 2001) . Group II mGluRs are also expressed on primary afferent terminals , but the role of peripheral group II mGluRs in nociception remains unknown. Systemic administration of group II mGluR agonists reduces inflammatory hyperalgesia (Sharpe et al., 2002) . We hypothesize that group II mGluR agonists may act through peripheral mechanisms to reduce nociception.
The necessity for the cAMP/PKA pathway in inflammatory hyperalgesia suggests that G i -coupled receptors might be targeted to reduce pain. Indeed, activation of G i -coupled -opioid and adenosine receptors produces analgesic effects (Joris et al., 1987; Taiwo and Levine, 1990; Karlsten et al., 1992) . Because group II mGluRs are coupled to G i , one mechanism by which group II mGluR agonists could reduce hyperalgesia is by inhibiting the cAMP/PKA pathway. The present study examined this hypothesis both in vivo and in vitro and demonstrated that peripheral group II mGluRs regulate PGE 2 -mediated sensitization, possibly by reversing PGE 2 -induced modulation of capsaicin receptors.
MATERIALS AND METHODS
Behavioral testing. Male ICR mice (6 -8 weeks of age; Taconic, Germantown, N Y) were allowed to recover for at least 2 d after arrival and habituated for at least 3 hr before experiments. Six mice were tested at approximately the same time on different days and divided into three groups with three different treatments.
Thermal sensitivity was measured as described previously (Bhave et al., 2001) . A light beam was applied to the plantar surface of the hindpaw (II TC Life Sciences, Woodland Hills, CA), and the foot withdrawal latency was measured. Before injections, baseline (time 0) was measured three times at an interval of ϳ10 min and averaged. After injections, withdrawal latency was measured at 30 min, 45 min, 1 hr, 1.5 hr, and 3 hr.
Stock solutions of 100 mM (2 R,4 R)-4-aminopy rrolidine-2,4-dicarbox ylate (A PDC) and 0.1 mM (2s)-2-amino-2-[(1s,2s)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495) (both from Tocris Cookson, Ballwin, MO) were made in 1 and 1.2 eq NaOH, respectively. A stock solution of 10 mg /ml PGE 2 (Sigma, St. L ouis, MO) was made in 100% ethanol. All drugs were diluted in 0.1 M PBS, pH 7.4. An equal amount of 100 mM HC l was added when diluting APDC to adjust the pH. All drugs were injected subcutaneously in a volume of 10 l into the plantar surface of the hindpaw. Appropriate vehicles were prepared as the diluents for each drug.
Cell culture. DRGs were isolated from 4-to 6-week-old ICR mice. Isolated ganglia were placed into 4°C PBS without Mg 2ϩ or C a 2ϩ (Invitrogen, Paisley, UK). Ganglia were incubated in 15 U/ml papain /Lcysteine (Worthington, Freehold, NJ) in HBSS (Invitrogen) for 20 min at 37°C, then washed with HBSS three times, followed by a 20 min incubation at 37°C in 1.5 mg /ml collagenase (Sigma) in HBSS. Ganglia were washed with HBSS three times before trituration with fire-polished Pasteur pipets. Dissociated cells were plated at ϳ3000 cells/ well on 12 mm glass coverslips coated with poly-D-lysine and collagen (Sigma). C ells were cultured for 5-6 d at 37°C in humidified air with 5% C O 2 . The culture medium contained neurobasal medium, 10% FBS, 100 U/ml penicillin /streptomycin, and 2 mM Glutamax (all from Invitrogen). In experiments in which pertussis toxin (P TX; Sigma) was used, 500 ng /ml P TX was added into the medium the night before. Calcium imag ing. C ells were loaded with 10 ng /ml f ura-2 AM (Molecular Probes, Eugene, OR) in HBSS for 1 hr and then washed three times and incubated in fresh HBSS for ϳ45 min before the experiments were performed. A coverslip was placed in the perf usion chamber (ϳ200 l volume) and perf used with HBSS at 2 ml /min. C ells were viewed under an inverted 1ϫ70 microscope (Olympus Optical, Tokyo, Japan). Images were captured with a Hamamatsu (Shizouka, Japan) Orca cooled charge-coupled device camera and recorded and analyzed using the SimplePCI software package with the dynamic intensity analysis module (Compix, T ualatin, OR) . Traces are all expressed as the ratio of fluorescence emission at an excitation wavelength of 357 and 380 nm, respectively. All experiments were performed at room temperature.
Drug application. (2 R,4 R)-APDC, LY341495, and PGE 2 stock solutions were made as described above. C apsaicin (Sigma) stock solution was made in ethanol. Forskolin (Sigma) stock solution was made in DMSO. I BMX (Sigma) and 8-bromo-cAM P (Sigma) stock solutions were made in deionized water. All drugs were diluted to final concentrations in HBSS and applied via bath perf usion.
Data anal ysis. Off-line analysis was performed using Microcal Origin (Microcal Software, Inc., Northampton, M A). Data are expressed as means Ϯ SEM. Treatment effects were analyzed by one-way ANOVA followed by T ukey's post hoc multiple comparisons using GraphPad Prism (GraphPad Software Inc., San Diego, CA). The time course of the effects of PGE 2 was analyzed by two-way ANOVA followed by Bonferroni post-tests. Error probabilities of p Ͻ 0.05 were considered statistically significant.
RESULTS

Activation of peripheral group II metabotropic glutamate receptors blocks prostaglandin E-induced thermal hyperalgesia
To test whether peripheral group II mGluRs can regulate thermal nociception, APDC, a selective group II mGluR agonist, was injected subcutaneously into the plantar surface of a mouse hindpaw. As shown in Figure 1b , APDC did not alter baseline thermal withdrawal latency, which is consistent with previous reports (Walker et al., 2001; Sharpe et al., 2002) . To test the hypothesis that group II mGluRs could play a role in nociception when responses to heat are sensitized by the activation of G scoupled receptors, 100 ng of PGE 2 was injected subcutaneously into the plantar surface of the hindpaw to induce thermal hyperalgesia. PGE 2 -induced thermal hyperalgesia lasted Ͼ1 hr and Figure 1 . Activation of peripheral group II mGluRs blocks PGE 2 -induced thermal hyperalgesia. a, PGE 2 (100 ng in 10 l) injected subcutaneously into the plantar surface of a mouse hindpaw decreased withdrawal latency to radiant heat applied to the hindpaw. Asterisks indicate time points at which PGE 2 (n ϭ 6) was significantly different from vehicle (n ϭ 7). b, Normalized thermal withdrawal latencies at 0.5, 0.75, and 1 hr were averaged and compared with baseline values. Injection of APDC (20 ng in 10 l; n ϭ 6) had no effect alone, but coinjection of APDC (n ϭ 6) blocked PGE 2 -induced hyperalgesia. LY341495 (0.2 ng in 10 l; n ϭ 7) blocked the APDC effect. c, At 3 hr, all groups were statistically indistinguishable from baseline. In all panels, dashed lines indicate the basal response.
peaked at or before 30 min (Fig. 1a) , which is consistent with previous results (Kerr et al., 2001) . Coinjection of APDC with PGE 2 blocked PGE 2 -induced thermal hyperalgesia (Fig. 1b) . LY341495, a selective group II mGluR antagonist, completely blocked the APDC effect (Fig. 1b) . Three hours after injection, when PGE 2 -induced hyperalgesia had recovered, all groups showed no significant difference from the baseline (Fig. 1c) .
Group II metabotropic glutamate receptors block prostaglandin E 2 -induced sensitization of capsaicin responses
The above results suggest that activation of peripheral group II mGluRs does not affect basal thermal sensitivity but blocks PGE 2 -induced thermal hyperalgesia. The VR1, or capsaicin receptor, is a key component of the thermal transduction machinery; it is critical for the development of thermal hyperalgesia (Caterina et al., 1997; Tominaga et al., 1998; Davis et al., 2000) . PGE 2 sensitizes capsaicin receptors by activating the cAMP/ PKA pathway (Pitchford and Levine, 1991; Lopshire and Nicol, 1998) . To test the hypothesis that group II mGluRs block PGE 2 -induced thermal hyperalgesia by blocking PGE 2 -induced potentiation of capsaicin receptor function, we investigated the effects of PGE 2 and APDC on capsaicin responses in cultured mouse DRG neurons.
VR1 is a cation channel that allows Na 2ϩ and Ca 2ϩ influx when activated by heat, protons, or capsaicin. Therefore, we studied VR1 function by measuring capsaicin-induced calcium influx into DRG neurons. In 20% of DRG neurons, application of capsaicin induced increases in intracellular Ca 2ϩ of varying amplitude and duration. Neurons with responses Ͻ10 min in duration were included in this study (Fig. 2) . Ten minutes after the first capsaicin application, a second identical capsaicin application produced a smaller response than the first, indicating desensitization of capsaicin receptors. The ratio of the amplitude of the second response to that of the first was calculated as the "response ratio."
As shown in Figure 2 , when PGE 2 was applied between the two capsaicin responses, the response ratio was significantly increased ( p Ͻ 0.001; ANOVA). When APDC alone was applied, there was no significant change in desensitization (Fig. 2) , which is consistent with our behavioral result that APDC did not change baseline thermal sensitivity. However, when APDC was coapplied with PGE 2 , the response ratio was significantly decreased compared with cells treated with PGE 2 ( p Ͻ 0.05; ANOVA). LY341495, a selective group II mGluR antagonist, completely blocked the effect of APDC ( p Ͻ 0.05), suggesting that the effects of APDC were attributable to the activation of group II mGluRs.
Group II metabotropic glutamate receptors block prostaglandin E 2 sensitization of capsaicin responses by activating G i and inhibiting AC
To test the hypothesis that group II mGluRs function by activating G i , we treated cells with PTX (500 ng/ml overnight) before calcium-imaging experiments. PTX induces ADP ribosylation of G i and impairs the interaction of G i with receptor-ligand complexes, uncoupling receptors from downstream second messenger systems (Hsia et al., 1984; Moss and Vaughan, 1984) . Treatment with PTX did not affect capsaicin responses or the effects of PGE 2 , whereas the effect of APDC was abolished (Fig. 3) .
Previous experiments suggest that group II mGluRs function by activating G i . To test the hypothesis that APDC blocks PGE 2 -induced sensitization by inhibiting AC, we investigated whether activation of group II mGluRs could block the effects of forskolin. Forskolin directly activates AC (Birnbaumer et al., 1983) , and this effect of forskolin can be inhibited by activation of G i (Hildebrandt et al., 1982) . cAM P synthesized by AC is rapidly metabolized within cells. To increase and prolong the effect of forskolin, we coapplied I BMX, an inhibitor of cAM P phosphodiesterase. Application of forskolin plus I BMX produced effects similar to those of PGE 2 (Fig. 4) . Application of APDC blocked the ability of forskolin to enhance capsaicin responses.
The results described above suggest that group II mGluRs block sensitization by PGE 2 or forskolin at or downstream of AC. Because IBMX is present, group II mGluRs were not acting on phosphodiesterases. To rule out the possibility that group II mGluRs are acting on PKA or other downstream effectors, we used 8-bromo-cAMP, a nonhydrolyzable analog of cAMP, to modulate capsaicin receptors. 8-Bromo-cAMP produced effects similar to those of PGE 2 (Fig. 4) . However, the effects of 8-bromo-cAMP were not blocked by APDC, suggesting that group II mGluRs are not acting on PKA or its downstream targets.
DISCUSSION
Agonists of group II mGluRs have been shown to act systemically as analgesics (Sharpe et al., 2002) . Furthermore, these drugs depress excitatory synaptic transmission in the substantia gelatinosa (Gerber et al., 2000) and block capsaicin-induced central sensitization in spinothalamic tract neurons (Neugebauer et al., 2000) . The observation that group II mGluRs are expressed on peripheral terminals of primary sensory neurons suggests that they might also act peripherally to produce antinociceptive effects. Here we have shown that group II mGluRs do not affect basal thermal nociception, but that activation of these receptors blocks the development of hyperalgesia induced by PGE 2 .
The fact that group II mGluRs couple to G i and the fact that the cAMP/PKA pathway is critical in the sensitization of nociception led us to hypothesize that the mechanism by which group II mGluRs block PGE 2 -induced thermal hyperalgesia is via inhibition of AC. PGE 2 significantly decreased desensitization of capsaicin-induced Ca 2ϩ influx in sensory neurons. Activation of group II mGluRs did not change capsaicin responses but significantly attenuated PGE 2 -induced sensitization, which is consistent with our findings that APDC had no effect on basal thermal sensation but did block PGE 2 -induced hyperalgesia. PTX treatment abolished this APDC effect. In agreement with previous reports that PGE 2 exerts its effects via the cAMP/PKA pathway, application of forskolin or 8-bromo-cAMP also sensitized capsaicin responses. Group II mGluR activation blocked the effects of forskolin plus IBMX but not the effect of 8-bromo-cAMP. These results indicate that group II mGluRs block PGE 2 -induced sensitization by activating G i and inhibiting AC.
Although there are many G i -coupled receptors, their inhibitory effects on AC were characterized primarily in heterologous expression systems in which overexpression of a protein might produce nonphysiological effects. Only in a very few cases have the physiological functions of a G i -coupled receptor been shown to be attributable to the inhibition of AC. Group II mGluRs are coupled to G i . In the CNS, the mechanism of these effects is poorly understood, despite the fact that they have been shown to produce various effects, including presynaptic modulation of synaptic transmission (Macek et al., 1996) and regulation of longterm depression and long-term potentiation (O'Leary and O'Connor, 1998; Otani et al., 1999) . The present study indicates that peripheral group II mGluRs attenuate PGE 2 -induced thermal hyperalgesia and suggests that this effect is mediated by blocking PGE 2 -mediated enhancement of capsaicin responses. Our results also indicate that this was attributable to the activation of G i and inhibition of AC after group II mGluR activation. Many inflammatory mediators, including PGE 2 (Cui and Nicol, 1995; Hingtgen et al., 1995; Mnich et al., 1995) , prostaglandin I 2 (Murata et al., 1997) , adenosine (Sawynok et al., 1997) , serotonin (Taiwo and Levine, 1992) , and 8 R,15S-dihydroxyeicosatetraenoic acid (Levine et al., 1986) , activate the cAMP/PKA pathway to induce hyperalgesia. Group II mGluR agonists are likely to inhibit the production of cAMP induced by other inflammatory mediators and, accordingly, might reduce the nociceptive sensitization induced by these agents.
It is interesting to note that the expression of group II mGluRs changes in several pain models. L-Acetylcarnitine, an analgesic used to treat neuropathic pain, acts by upregulating mGluR2 in DRG neurons (Chiechio et al., 2002) . UV-irradiation-induced peripheral inflammation increases the expression of mGluR3 mRNA in the dorsal horn (Boxall et al., 1998) . mGluR3 mRNA is increased in the cerebral cortex of monoarthritic rats (Neto et al., 2001) . Although our results suggest that activation of peripheral group II mGluRs can fully block PGE 2 -induced thermal hyperalgesia, it would be interesting to investigate whether they have more significant effects in prolonged pain models.
We have shown recently that peripheral group I mGluRs also modulate nociception. Peripherally applied (RS)-3,5-dihydroxyphenylglycine, a selective group I mGluR agonist, dosedependently induces thermal hyperalgesia; antagonists of group I mGluRs can prevent and attenuate formalin-induced pain (Bhave et al., 2001 ). The present data indicate that peripheral group II mGluRs play an opposing role in modulating nociception. During inflammation, glutamate is released into the peripheral injury site and is thought to play a role in inducing inflammatory pain. Although it is unknown whether group I mGluRs and group II mGluRs are colocalized in the same peripheral sensory afferents, the activation of group II mGluRs might act as a balancing mechanism to counteract some of the effects of glutamate. It would be interesting to investigate whether group II mGluRs provide tonic inhibition of nociception and whether inhibition of group II mGluRs would result in more significant nociceptive sensitization. As mentioned above, the expression of group II mGluRs increases in several pain models; this might act as a protective mechanism to prevent additional sensitization of nociception in situations in which nociceptive thresholds are already decreased. Additional experiments will need to be performed to investigate whether glutamate acts to induce hyperalgesia at the beginning of inflammation while at the same time producing an analgesic effect during prolonged inflammation when there are more group II mGluRs present.
Our study is the first to demonstrate a role for peripheral group II mGluRs in the modulation of nociception. These results do not rule out the possibility that group II mGluRs also modulate inflammatory pain through central mechanisms. However, our results indicate that activation of peripheral group II mGluRs completely blocks the thermal hyperalgesia induced by PGE 2 . In addition to the induction of inflammatory pain, PGE 2 might also contribute to the maintenance or progression of inflammatory pain, because inflammation can be accompanied by a sustained increase in PGE 2 levels (Davies et al., 1984) . Peripheral group II mGluRs can potentially be targeted to control inflammatory pain while at the same time avoiding the possible CNS side effects of systemic administration.
